The study not only demonstrated no additional benefit of combination immunotherapy in patients with EGFR-mutant NSCLC but also implied the contradictory role of PD-L1 expression in predicting response to EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.